Philippe Schafhausen

4.5k total citations · 1 hit paper
70 papers, 2.0k citations indexed

About

Philippe Schafhausen is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Philippe Schafhausen has authored 70 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 34 papers in Genetics and 25 papers in Oncology. Recurrent topics in Philippe Schafhausen's work include Chronic Myeloid Leukemia Treatments (30 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Head and Neck Cancer Studies (15 papers). Philippe Schafhausen is often cited by papers focused on Chronic Myeloid Leukemia Treatments (30 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Head and Neck Cancer Studies (15 papers). Philippe Schafhausen collaborates with scholars based in Germany, United States and Italy. Philippe Schafhausen's co-authors include Walter Fiedler, Gunter Schuch, Dieter K. Hossfeld, Ursula M. Gehling, Süleyman Ergün, Klaus Pantel, Birgit Schäfer, Marcus Otte, Udo Schumacher and Christoph Wagener and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Philippe Schafhausen

64 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In vitro differentiation of endothelial cells from AC133-positive progenitor cells

2000 795 citations Philippe Schafhausen, Dieter K. Hossfeld et al. profile →

Peers

Countries citing papers authored by Philippe Schafhausen

Since Specialization

Citations

This map shows the geographic impact of Philippe Schafhausen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Schafhausen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Schafhausen more than expected).

Fields of papers citing papers by Philippe Schafhausen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Schafhausen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Schafhausen. The network helps show where Philippe Schafhausen may publish in the future.

Co-authorship network of co-authors of Philippe Schafhausen

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Schafhausen. A scholar is included among the top collaborators of Philippe Schafhausen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Schafhausen. Philippe Schafhausen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer 2025 ·npj Precision Oncology ·Lisa Paschold, Christoph Schultheiß, (unknown), Konrad Klinghammer, D Hahn, Mareike Tometten, Philippe Schafhausen, (unknown), Anna Brandt, (unknown), (unknown), Alexander Stein, Axel Hinke, Mascha Binder	0
2	Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma 2023 ·Frontiers in Oncology ·Damian Rieke, (unknown), Philippe Schafhausen, Eric Blanc, (unknown), (unknown), Dieter Beule, Ulrich Keller, Ulrich Keilholz, Konrad Klinghammer	5
3	Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia 2022 ·Thrombosis Research ·(unknown), Christina C. Rolling, Ulrich Budde, (unknown), Philippe Schafhausen, (unknown), Carsten Bokemeyer, Katharina Holstein, Florian Länger	4
4	A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study 2021 ·ESMO Open ·Konrad Klinghammer, Jérôme Fayette, Andrzej Kawecki, Andreas Dietz, Philippe Schafhausen, Gunnar Folprecht, Sylvie Rottey, P. Debourdeau, Javier Lavernia, Adam Jacobs, (unknown), (unknown), Harald Baumeister, Alfredo Zurlo, Sebastian Ochsenreither, Ulrich Keilholz	6
5	Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg 2020 ·Oncology Research and Treatment ·Katja Weisel, (unknown), Cordula Petersen, Walter Fiedler, Andreas Block, Philippe Schafhausen, Johannes K.‐M. Knobloch, Carsten Bokemeyer	26
6	Usability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients 2019 ·PLoS ONE ·Lena M. Biehl, Debora Garzetti, Fedja Farowski, Diana Ring, (unknown), Holger Rohde, Philippe Schafhausen, Bärbel Stecher, Maria J. G. T. Vehreschild	27
7	Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial 2016 ·Haematologica ·Haifa Kathrin Al‐Ali, Martin Grießhammer, Philipp le Coutre, Cornelius F. Waller, A. M. Liberati, Philippe Schafhausen, Renato Tavares Daher, Pilar Giraldo, Lynda Foltz, Pia Raanani, Vikas Gupta, (unknown), Julian Perez Ronco, Jaya Ghosh, B. Martino, Alessandro M. Vannucchi	119
8	Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis 2016 ·Leukemia ·Richard F. Schlenk, Frank Stegelmann, Andreas Reiter, Edgar Jost, Norbert Gattermann, Holger Hebart, Cornelius F. Waller, Andreas Hochhaus, Uwe Platzbecker, Philippe Schafhausen, Igor‐Wolfgang Blau, Walter Verbeek, Florian H. Heidel, Martin Werner, Hans Kreipe, Veronica Teleanu, Axel Benner, Hartmut Döhner, Martin Grießhammer, Konstanze Döhner	14
9	The current role of systemic chemotherapy in the primary treatment of head and neck cancer 2015 ·Cancer Treatment Reviews ·Chia‐Jung Busch, Silke Tribius, Philippe Schafhausen, Rainald Knecht	25
10	A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies 2014 ·Journal of Antimicrobial Chemotherapy ·Maria J. G. T. Vehreschild, Axel Hamprecht, Lance R. Peterson, Sören Schubert, Maik Häntschel, Silke Peter, Philippe Schafhausen, Holger Rohde, Marie von Lilienfeld‐Toal, Isabelle Bekeredjian‐Ding, (unknown), Martin Hellmich, Jörg Janne Vehreschild, Oliver A. Cornely, Harald Seifert	74
11	Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor 2014 ·Recent results in cancer research ·Susanne Isfort, (unknown), Philippe Schafhausen, Steffen Koschmieder, Tim H. Brümmendorf	22
12	Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity 2013 ·International Journal of Hematology ·Lars Harbaum, Andreas H. Marx, Eray Goekkurt, Philippe Schafhausen, Djordje Atanackovic	10
13	Die wichtigsten Studienergebnisse der primären Radio-Chemo-Therapie von Kopf-Hals-Tumoren 2013 ·HNO ·Adrian Münscher, Chia‐Jung Busch, Philippe Schafhausen, Silke Tribius, Rainald Knecht	1
14	Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy 2012 ·Annals of Hematology ·Anthony Oyekunle, Axel R. Zander, Mascha Binder, Francis Ayuk, Tatjana Zabelina, Maximilian Christopeit, Thomas Stübig, Haefaa Alchalby, Philippe Schafhausen, Heinrich Lellek, Christine Wolschke, Ingo Müller, Ulrike Bacher, Nicolaus Kröger	28
15	Molecular targeting agents in the context of primary chemoradiation strategies 2012 ·Head & Neck ·Simon Laban, (unknown), Adrian Münscher, Silke Tribius, Philippe Schafhausen, Rainald Knecht	3
16	Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis 2010 ·Leukemia & lymphoma ·Tanja Stahl, Anita Badbaran, Nicolaus Kröger, Evgeny Klyuchnikov, Tatjana Zabelina, (unknown), Philippe Schafhausen, (unknown), (unknown), (unknown), Christine Wolschke, Francis Ayuk, Axel R. Zander, Boris Fehse, Ulrike Bacher	18
17	Bosutinib 2009 ·Recent results in cancer research ·Gunhild Keller, Philippe Schafhausen, Tim H. Brümmendorf	21
18	Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia 2009 ·Expert Review of Hematology ·Gunhild Keller, Philippe Schafhausen, Tim H. Brümmendorf	27
19	Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative 2008 ·British Journal of Haematology ·(unknown), Alexander Schultze, Philippe Schafhausen, (unknown), Judith Dierlamm, Carsten Bokemeyer, Tim H. Brümmendorf, Walter Fiedler, Sonja Loges	17
20	A novel cryptic translocation t(12;17)(p13;p12–p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene 2003 ·Genes Chromosomes and Cancer ·Eva Maria Murga Penas, Jan Cools, Petra Algenstaedt, Kristina Hinz, Doris R. Seeger, Philippe Schafhausen, Georgia Schilling, Peter Marynen, Dieter K. Hossfeld, Judith Dierlamm	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact